Table 3 Treatment factors of transarterial chemoembolization (patients, N = 35) (total DEB-TACE, N = 66)
TACE intervention timing (n = 35) | |
 1st line therapy failure | 19 (54.3%) |
 2nd line therapy failure | 10 (28.5%) |
 3rd line therapy failure | 5 (14.3%) |
 4th line therapy failure | 1 (2.9%) |
No. of liver metastasis (n = 35) | |
 1 | 6 (17.1%) |
 2 | 2 (5.7%) |
 4 | 1 (2.9%) |
 ≧5 | 26 (74.3%) |
Location of liver metastasis (n = 35) | |
 Right lobe | 10 (28.6%) |
 Left lobe | 0 (0%) |
 Both lobes | 25 (71.4%) |
Tumor burden of liver (n = 35) | |
 10 ~ 30% | 19 (54.3%) |
 30 ~ 50% | 10 (28.6%) |
 50 ~ 70% | 6 (17.1%) |
Number of DEB-TACE courses (n = 35) | |
 1 | 19 (54.3%) |
 2 | 8 (22.8%) |
 3 | 4 (11.4%) |
 4 | 1 (2.9%) |
 5 | 3 (8.6%) |
 Median | 1 |
Total embolization numbers | 66 |
DEB-TACE agent (n = 66) | |
 Irinotecan | 60 (90.9%) |
 Epirubicin | 6 (9.1%) |
Best response (n = 35) | |
 Partial response (PR) | 5 (14.3%) |
 Stable disease (SD) | 14 (40.0%) |
 Progressive disease (PD) | 13 (37.1%) |
 Not availablea | 3 (8.6%) |
 Disease control rate (PR + SD) | 19 (54.3%) |